Introduction {#sec1}
============

Chemiluminescence based on the luminol reaction is used for many different applications (details in the [Discussion](#sec3){ref-type="other"} section). The reaction mechanism is complex and needs alkaline pH to provide luminol monoanion (LH^--^) and involves diverse intermediates such as a radical form of luminol (L^--•^), azaquinone (AQ) and finally the light-emitting species aminophthalate (AP\*). The reaction is most efficiently catalyzed by heme proteins. However, the light yield of the reaction decays under harsh oxidizing conditions (\[H~2~O~2~\] ≥ 1 mM). This "suicide inactivation" is an undesired effect when the luminol reaction is to be used with quantitative assays. Strategies have been reported to avoid "suicide inactivation" by improving the heme catalyst.^[@ref1]−[@ref9]^ However, the precise adjustment of the assay ingredients can generate a long-lasting glow-type luminescence of high intensity.^[@ref10],[@ref11]^ This study is intended to demonstrate the diversity of compounds which are able to boost or otherwise influence the luminol reaction. It shows how important the balance of the two substrates (i.e., luminol and peroxide) is and how the light yield and luminescence kinetics are amplified or reduced by phenolic compounds, antioxidants (AOs), or reducing agents. Experiments are presented, which allow a ranking of reducing agents with respect to their redox potential relative to the substrates and catalysts of the luminol reaction. Finally, important considerations necessary for the design of sensitive and highly specific quantitative luminol-based assays are discussed.

Results {#sec2}
=======

Luminol Protects Heme Catalysts from Peroxide-Induced "Suicide Inactivation" {#sec2.1}
----------------------------------------------------------------------------

Luminol (LH^--^) delivers electrons to heme and thereby prevents the over-oxidation and disintegration of the catalytic center by H~2~O~2~. This protective effect of luminol can be verified when the dependency of luminescence on \[H~2~O~2~\] is studied at various luminol concentrations. The data ([Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}) clearly show that the inhibition of the horseradish peroxidase (HRP)-catalyzed luminol reaction by H~2~O~2~ shifts toward higher \[H~2~O~2~\] when \[LH^--^\] is increased. The effective concentrations for 50% inhibition (IC~50~) were determined for each \[LH^--^\] by sigmoidal four-parametric logistic fit of the data ([Supporting Information](http://pubs.acs.org/doi/suppl/10.1021/acsomega.8b01261/suppl_file/ao8b01261_si_001.pdf), Table S1.1).

![Dependence of luminescence on \[H~2~O~2~\] and luminol concentration \[LH^--^\] with HRP as the catalyst and protection from "suicide inactivation". (A) Luminescence, integrated over the first 15 min of the reaction, is plotted against \[H~2~O~2~\]. The reactions were started by injecting a mixture of the catalyst and luminol into a H~2~O~2~ solution to reach the following assay conditions: 100 mM Tris/HCl pH = 9; \[HRP\] = 2.5 μg/mL; \[LH^--^\] as indicated in the inset; and \[H~2~O~2~\] is given by the abscissa. (B) Data (*I*~LY~) were normalized by the mean of each data set to facilitate direct comparison. Data are the averages of *n* = 4 technical replicates. The error bars represent standard deviation (SD). SD is below the symbol size, where no error bar can be seen.](ao-2018-01261f_0001){#fig1}

This shows that as more luminol is consumed, the "suicide inactivation" effect is shifted more toward higher \[H~2~O~2~\]. Doubling \[LH^--^\] roughly doubled IC~50~. Similar results were obtained with Cyt *c* ([Supporting Information](http://pubs.acs.org/doi/suppl/10.1021/acsomega.8b01261/suppl_file/ao8b01261_si_001.pdf), Figure S1).

Reducing Agents Quench Luminescence and Exert a Delay Effect on the Light-Yielding Reaction {#sec2.2}
-------------------------------------------------------------------------------------------

Because luminol protects the catalysts from "suicide inactivation" ([Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}; [Supporting Information](http://pubs.acs.org/doi/suppl/10.1021/acsomega.8b01261/suppl_file/ao8b01261_si_001.pdf), Figure S1) and thereby exerts an antioxidative effect on the catalytic heme core, the effect of other AOs on heme destruction by high \[H~2~O~2~\] was tested. The most abundant AO found in vivo is glutathione (GSH). Therefore, the sensitivity of HRP to high \[H~2~O~2~\] was tested using GSH as described above. The results ([Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}) reveal that GSH reduces the luminescence significantly but does not exert a protective effect on HRP. This can be seen directly because the peroxide-based inhibition does not shift toward higher \[H~2~O~2~\] ([Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}) as was observed when \[LH^--^\] was varied ([Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}). The IC~50~ values calculated from this data set ([Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}) are presented in the [Supporting Information](http://pubs.acs.org/doi/suppl/10.1021/acsomega.8b01261/suppl_file/ao8b01261_si_001.pdf) (Table S1.2).

![Dependence of luminescence on \[H~2~O~2~\] and GSH concentration with HRP as the catalyst. Assay conditions: 100 mM Tris/HCl pH = 9; \[LH^--^\] = 750 μM; \[HRP\] = 2 μg/mL; \[GSH\] is indicated in the inset; and the luminescence is plotted against \[H~2~O~2~\]. The luminescence data represent light yield (*I*~LY~) integrated over the first 15 min of the reaction. Data are the averages of *n* = 3 technical replicates. Error bars represent SD. SD is below the symbol size, where no error bar can be seen.](ao-2018-01261f_0002){#fig2}

There are three possible mechanisms which may explain the reduction of light yield (i.e., luminescence quenching) caused by GSH as shown in [Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}:\#1The catalyst abstracts electrons from GSH to produce GS^•^ radicals ([eq [1](#eq1){ref-type="disp-formula"}](#eq1){ref-type="disp-formula"}), which lead to the oxidized form GSSG ([eq [2](#eq2){ref-type="disp-formula"}](#eq2){ref-type="disp-formula"}).\#2GSH is in competition with luminol radicals L^--•^, donating H^+^ and e^--^ to L^--•^, thus recycling it back to LH^--^, and thereby preventing the light-yielding reaction ([eq [3](#eq3){ref-type="disp-formula"}](#eq3){ref-type="disp-formula"}).

This would imply that GS^•^ has a redox potential that is too low to abstract e^--^ from LH^--^.\#3The catalyst is permanently inhibited by GSH and thus inactivated. Luminescence is thereby permanently quenched because of a decrease of the heme catalyst concentration.

The first two mechanisms imply that GSH renders the catalyzed luminol reaction futile. GSH is consumed either by the catalyst ([eqs [1](#eq1){ref-type="disp-formula"}](#eq1){ref-type="disp-formula"} and [2](#eq2){ref-type="disp-formula"}) or by L^--•^ ([eq [3](#eq3){ref-type="disp-formula"}](#eq3){ref-type="disp-formula"}) and thus constitutes a factor that only transiently disturbs the luminol reaction, as long as GSH is present.

The kinetics ([Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}A,C) indeed reveal that the light yield is low in the presence of GSH but resumes as soon as all GSH is consumed. Both the extent of luminescence quenching during the delay period ([Figure [4](#fig4){ref-type="fig"}](#fig4){ref-type="fig"}A, the quenching effect) and the duration of the delay period until the reaction resumes light emission depend on \[GSH\] ([Supporting Information](http://pubs.acs.org/doi/suppl/10.1021/acsomega.8b01261/suppl_file/ao8b01261_si_001.pdf), Figure S2B). This effect was observed even at the nanomolar concentrations of GSH and confirms that the catalyst is not permanently affected (i.e., mechanism \#3 does not apply).

![Effect of GSH and NADH on the kinetics of the luminol reaction catalyzed by HRP and Cyt *c*. (A) Luminol luminescence catalyzed by HRP is quenched and delayed by GSH. It resumes when all AOs in the reaction are consumed. The lower the \[GSH\], the shorter is the luminescence delay time. (B) Same effect is observed with NADH as an AO. (C) GSH is also able to quench and delay luminescence when it is catalyzed by Cyt *c*. (D) However, when the experiment is performed with NADH, no delay effect can be seen, when Cyt *c* is the catalyst. Instead, luminescence is permanently quenched because Cyt *c* is reduced by NADH in the presence of H~2~O~2~, and thereby, the catalyst is withdrawn from the reaction. The reactions were started by injecting H~2~O~2~ into a mixture of the catalyst, luminol, and the reducing agent to reach the following assay conditions: Tris/HCl 100 mM pH = 9; \[Cyt *c*\] = 20 μg/mL; HRP 0.75 μg/mL; \[LH^--^\] = 750 μM;. \[H~2~O~2~ \] = 1.1 mM; and reducing agents as indicated in the insets in micromolar.](ao-2018-01261f_0003){#fig3}

![Initial quenching effect of GSH and NADH on the luminol reaction catalyzed by diverse catalysts. Various concentrations of GSH and NADH were tested for their ability to reduce the light emission of the luminol reaction. The relative light yield integrated over the first minute of each reaction is plotted against the respective concentration of GSH (A) and NADH (B). Data are normalized by the luminescence obtained without AOs. The reactions were started by injecting H~2~O~2~ into a mixture of the catalyst, luminol, and the reducing agent to reach the following assay conditions: Tris/HCl 100 mM pH = 9; \[LH^--^\] = 750 μM; \[H~2~O~2~\] = 1.1 mM; and catalysts are indicated in the inset: \[HRP\] = 0.75 μg/mL; \[Cyt *c*\] = 15 μg/mL; \[Hemin\] = 1 μM; \[Hb\] = 20 μg/mL; and \[FeEDDHA\] = 200 μM; data are means of *n* = 3 technical replicates. Error bars represent SD. SD is below the symbol size where no error bar can be seen.](ao-2018-01261f_0004){#fig4}

However, the delay effect on light production was not observed with all reducing agents and catalysts. This is because some reducing agents directly affect the catalyst and thereby decrease its light-yielding efficiency by mechanism \#3 mentioned above. This is demonstrated with Cyt *c* ([Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}C,D). Nicotinamide--adenine--dinucleotide disodium (NADH) is the most abundant redox cofactor in living cells and is able to affect Cyt *c* in the presence of peroxides.^[@ref12]^ This results in permanent luminescence quenching by NADH ([Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}D), and the kinetics do not exhibit the onset of delayed light yield. GSH in contrast seems not to affect Cyt *c* ([Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}C).

A quenching effect, be it produced by a futile cycle (mechanisms \#1 and \#2) or by the inactivation of the catalyst (mechanism \#3), can be observed with any reducing agent and any catalyst that drives the luminol reaction. The curves ([Figure [4](#fig4){ref-type="fig"}](#fig4){ref-type="fig"}) showing the initial degree of luminescence quenching with respect to the concentration of the reducing agent in the assay are possibly characteristic for the redox potential of the involved reducing agent relative to the potential of H~2~O~2~, catalyst, and luminol. Other tested reducing agents (ascorbate, dithiothreitol, uric acid, trolox, and sulfite) produce other characteristic inhibition curves with each catalyst ([Supporting Information](http://pubs.acs.org/doi/suppl/10.1021/acsomega.8b01261/suppl_file/ao8b01261_si_001.pdf), Figure S3.1).

Enhancement of Luminescence by Aromatic Hydrogen (AH) Donors {#sec2.3}
------------------------------------------------------------

The luminol reaction driven by a genuine peroxidase can be enhanced by a number of aromatic compounds.^[@ref13]−[@ref19]^ Such compounds are typical hydrogen donors (AH), which are preferably accepted by the peroxidase as substrates. However, at low concentrations, they do not inhibit the light-yielding reaction as AOs do but rather boost it by orders of magnitude ([Figure [5](#fig5){ref-type="fig"}](#fig5){ref-type="fig"}) because their radical form (A^•^) abstracts hydrogen from luminol.^[@ref18]^ In this way, they are able to work as redox mediators and thus amplify the turnover and oxidation power of the catalyst.

![Effect of IP on the luminol reaction catalyzed by various catalysts. Various concentrations of IP were tested for their ability to boost the light-yielding reaction. The relative light yield of each reaction is plotted against the respective IP concentration. Only the HRP-catalyzed reaction is enhanced by a factor of about 40, when \[IP\] is around 200 μM. The efficiency of other catalysts cannot be enhanced by IP. The reactions were started by injecting H~2~O~2~ into a mixture of the catalyst, luminol, and IP to reach the following assay conditions: Tris/HCl 100 mM pH = 9; \[LH^--^\] = 750 μM; \[H~2~O~2~\] = 1.1 mM; and catalysts are indicated in the inset: \[HRP\] = 0.375 μg/mL; \[Cyt *c*\] = 3.75 μg/mL; \[Hemin\] = 1.5 μM; \[FeEDDHA\] = 200 μM; and \[Hb\] = 20 μg/mL. Data are normalized by the luminescence obtained without IP. Data are means of *n* = 4 technical replicates. Error bars represent SD. SD is below the symbol size where no error bar can be seen.](ao-2018-01261f_0005){#fig5}

It is important to note that the enhancing effect is only seen with HRP (green symbols, [Figure [5](#fig5){ref-type="fig"}](#fig5){ref-type="fig"}). There is an optimal concentration of enhancers giving the HRP reaction a maximum boost of light emission by a factor of 10--100 ([Figure [5](#fig5){ref-type="fig"}](#fig5){ref-type="fig"}; [Supporting Information](http://pubs.acs.org/doi/suppl/10.1021/acsomega.8b01261/suppl_file/ao8b01261_si_001.pdf), Figure S4.1). The luminol reaction driven by other heme catalysts (i.e., the so-called "pseudo-peroxidases") cannot be enhanced this way. Enhancers at high concentrations inhibit the light reaction with all other catalysts tested ([Figure [5](#fig5){ref-type="fig"}](#fig5){ref-type="fig"}). This effect is comparable with the luminescence quenching caused by AOs ([Figure [4](#fig4){ref-type="fig"}](#fig4){ref-type="fig"}). Similar results to those in [Figure [5](#fig5){ref-type="fig"}](#fig5){ref-type="fig"} have been obtained with benzidine and coumarin as enhancers ([Supporting Information](http://pubs.acs.org/doi/suppl/10.1021/acsomega.8b01261/suppl_file/ao8b01261_si_001.pdf), Figure S4.1).

Enhancers Protect HRP from Peroxide-Induced "Suicide Inactivation" {#sec2.4}
------------------------------------------------------------------

Apart from boosting the reaction, the enhancers also protect the HRP from "suicide inactivation" ([Figure [6](#fig6){ref-type="fig"}](#fig6){ref-type="fig"}). With an increasing enhancer concentration, the inhibitory effect shifts toward higher \[H~2~O~2~\]. The half-inhibitory H~2~O~2~ concentration (IC~50~) correlates and increases with increasing \[IP\] ([Supporting Information](http://pubs.acs.org/doi/suppl/10.1021/acsomega.8b01261/suppl_file/ao8b01261_si_001.pdf), Table S4.1). This effect is similar to that seen when the luminol concentration is increased ([Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}; [Supporting Information](http://pubs.acs.org/doi/suppl/10.1021/acsomega.8b01261/suppl_file/ao8b01261_si_001.pdf), Table S1.1) and confirms the direct interaction of the enhancer with HRP.

![Dependence of luminescence on \[H~2~O~2~\] and IP and the protection from "suicide inhibition". \[IP\] is indicated in the inset, and luminescence is plotted against \[H~2~O~2~\] in order to demonstrate that the peroxide-induced inhibition of the reaction shifts toward higher \[H~2~O~2~\] with increasing \[IP\]. The reactions were started by injecting H~2~O~2~ into a mixture of HRP, luminol, and IP to reach the following assay conditions: Tris/HCl 100 mM pH = 9; \[LH^--^\] = 750 μM; \[HRP\] = 0.125 μg/mL; data are averages of *n* = 3 technical replicates. Error bars represent SD. SD is below the symbol size, where no error bar can be seen.](ao-2018-01261f_0006){#fig6}

Discussion {#sec3}
==========

The "suicide inactivation" caused by H~2~O~2~ and the antioxidative "shielding effect" of LH^--^, which lowers the sensitivity of the heme catalyst to H~2~O~2~, is demonstrated in [Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"} and [Supporting Information](http://pubs.acs.org/doi/suppl/10.1021/acsomega.8b01261/suppl_file/ao8b01261_si_001.pdf) (Figure S1 and Table S1.1). Shielding is efficient as long as there is a balance between \[H~2~O~2~\] and \[LH^--^\] in the assay (i.e., \[LH^--^\] ≥ \[H~2~O~2~\]). A large excess of \[H~2~O~2~\] over \[LH^--^\] leads to the destruction of the heme catalyst. A similar "shielding effect" is also seen with the enhancers of the HRP-catalyzed reaction such as iodophenol (IP) or benzidine ([Figure [6](#fig6){ref-type="fig"}](#fig6){ref-type="fig"}; [Supporting Information](http://pubs.acs.org/doi/suppl/10.1021/acsomega.8b01261/suppl_file/ao8b01261_si_001.pdf), Figure S4.2 and Table S4.1). This suggests that, like luminol, the enhancers are also accepted by HRP as substrates. They exhibit a concentration optimum, providing a maximum enhancement of light yield (*I*~LY~). Here ([Figure [5](#fig5){ref-type="fig"}](#fig5){ref-type="fig"}), the IP concentration for maximal enhancement of the HRP-catalyzed reaction is around 200 μM, which is in good agreement with the results reported by Bhandari et al.^[@ref20]^ In contrast, Yakunin and Hallenbeck^[@ref21]^ reported a maximal enhancement at \[IP\] = 4 mM, which might be caused by the much higher \[H~2~O~2~\] of 17.6 mM they used. For optimal enhancement and minimal "suicide inactivation", luminol, enhancer, and peroxide concentrations must be well balanced. Consequently, at \[H~2~O~2~\] = 17.6 mM, an equivalent high enhancer concentration (4 mM) was necessary to prevent "suicide inactivation".^[@ref21]^

Luminol reactions catalyzed by heme compounds other than HRP (i.e., Cyt *c*, Hb, and Hemin) could not be enhanced by the phenolic compounds tested here. Their integrated light yield (*I*~LY~) decreases with increasing enhancer concentrations ([Figure [5](#fig5){ref-type="fig"}](#fig5){ref-type="fig"}; [Supporting Information S4.1](http://pubs.acs.org/doi/suppl/10.1021/acsomega.8b01261/suppl_file/ao8b01261_si_001.pdf)) as it does with nonenhancing AOs ([Figure [4](#fig4){ref-type="fig"}](#fig4){ref-type="fig"}; [Supporting Information](http://pubs.acs.org/doi/suppl/10.1021/acsomega.8b01261/suppl_file/ao8b01261_si_001.pdf), Figure S3.1). In the following, it is discussed how this can reveal details about the redox properties of these catalysts.

Luminescence Quenching and Delay Are Caused by AOs {#sec3.1}
--------------------------------------------------

Any reducing agent or AO can interfere with the peroxidative cycle and thereby inhibit the light-yielding luminol reaction to some extent ([Figure [4](#fig4){ref-type="fig"}](#fig4){ref-type="fig"}; and [Supporting Information](http://pubs.acs.org/doi/suppl/10.1021/acsomega.8b01261/suppl_file/ao8b01261_si_001.pdf), Figure S3.1). Generalizing the assumptions made for GSH above ([eqs [1](#eq1){ref-type="disp-formula"}](#eq1){ref-type="disp-formula"}--[3](#eq3){ref-type="disp-formula"}), different mechanisms of interference are imaginable ([Figure [7](#fig7){ref-type="fig"}](#fig7){ref-type="fig"}), which depend on the relative redox potentials of the AO, L, and catalyst:\#1AO~red~ serves as an immediate donor, delivering electrons to the catalyst and the resulting radicals (AO^•^) form an oxidized product AO~ox~ ([Figure [7](#fig7){ref-type="fig"}](#fig7){ref-type="fig"}A). In this way, luminol is left unaltered as long as the peroxidative cycle is busy with AO~red~. This suggests that the catalyst prefers AO~red~ and rejects LH^--^ as a substrate, possibly because of the more negative redox potential of AO~red~ relative to LH^--^. If AO~red~ was GSH, then this scheme ([Figure [7](#fig7){ref-type="fig"}](#fig7){ref-type="fig"}A) would resemble the activity of a GSH peroxidase.^[@ref22]^\#2The peroxidative cycle abstracts electrons preferably from LH^--^ to produce L^--•^. However, L^--•^ is scavenged by AO~red~ and therefore cannot yield light ([Figure [7](#fig7){ref-type="fig"}](#fig7){ref-type="fig"}B) because \[AO~red~\] is in excess over \[L^--•^\]. Instead, it is recycled in a futile cycle. This implies that AO~red~ has a negative redox potential relative to L^--•^ and that AO^•^ is unable to exchange electrons with L^•--^.^[@ref18]^\#3AO~red~ in combination with H~2~O~2~ inactivates the heme catalyst and thus eliminates it from the reaction cycle ([Figure [7](#fig7){ref-type="fig"}](#fig7){ref-type="fig"}C). This may occur via a reduction of the protein by opening of disulfide bridges in combination with a reductive liberation of Fe^II^ or Fe^III^ from the heme.^[@ref12]^ Consequently, luminescence is quenched by the depletion of the heme catalyst with no recovery of light emission ([Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}D), whereas a light emission recovery ([Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}A--C; [Supporting Information](http://pubs.acs.org/doi/suppl/10.1021/acsomega.8b01261/suppl_file/ao8b01261_si_001.pdf), Figure S2A) can be explained only by one of the first two mechanisms ([Figure [7](#fig7){ref-type="fig"}](#fig7){ref-type="fig"}A,B).

![Possible mechanisms explaining the interference of AOs with the luminol reaction catalyzed by the peroxidative cycle. The light yield of the peroxidase-catalyzed luminol reaction is reduced as long as a competitive AO (AO~red~) is present. AO~red~ is turned into its oxidized form (AO~ox~) by the peroxidative cycle and thus competes with luminol. Depending on its reduction power, AO~red~ interferes directly and exclusively with the catalyst, leaving LH^--^ unattached (A) or it recycles L^--•^ back to LH^--^ in a futile cycle (B). These scenarios (A,B) imply that light emission resumes as soon as all AO~red~ is consumed and converted into AO~ox~. No resumption of light emission occurs when AO~red~ in collaboration with H~2~O~2~ inactivates the catalyst irreversibly (C).](ao-2018-01261f_0007){#fig7}

Although [Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"} and [Supporting Information](http://pubs.acs.org/doi/suppl/10.1021/acsomega.8b01261/suppl_file/ao8b01261_si_001.pdf) (Figure S1) demonstrate that a reducing substrate (here LH^--^) can protect the heme core of the catalyst from being destroyed by H~2~O~2~, this is not generally the case for any other reducing agent (AO~red~). In the presence of GSH, for instance, the light yield of the reaction is drastically reduced ([Figures [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}A,C; [4](#fig4){ref-type="fig"}A), but the inhibitory effect of H~2~O~2~ is not shifted toward higher \[H~2~O~2~\] ([Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}; [Supporting Information](http://pubs.acs.org/doi/suppl/10.1021/acsomega.8b01261/suppl_file/ao8b01261_si_001.pdf), Table S1.2) as is the case for luminol ([Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}; [Supporting Information](http://pubs.acs.org/doi/suppl/10.1021/acsomega.8b01261/suppl_file/ao8b01261_si_001.pdf), Table S1). Thus, it is reasonable to assume that mechanism \#1 ([Figure [7](#fig7){ref-type="fig"}](#fig7){ref-type="fig"}A) does not apply and that GSH does not directly interact with the catalyst but rather draws electrons from L^--•^ to become GSSH according to mechanism \#2 ([eq [3](#eq3){ref-type="disp-formula"}](#eq3){ref-type="disp-formula"} and [Figure [7](#fig7){ref-type="fig"}](#fig7){ref-type="fig"}B). A similar mechanism of GSH oxidation has been proposed earlier for quinones other than luminol.^[@ref23]^

When the extent of luminescence quenching is plotted against the concentration of the respective AO~red~ ([Figure [4](#fig4){ref-type="fig"}](#fig4){ref-type="fig"}), it is evident that there are different mechanisms by which the reducing agent affects the catalysis of the luminol reaction. GSH for instance starts to produce an effect on the Cyt *c*-catalyzed reaction at a concentration of about 10 μM (pink symbols in [Figure [4](#fig4){ref-type="fig"}](#fig4){ref-type="fig"}A), whereas higher NADH concentrations (80 μM; pink symbols in [Figure [4](#fig4){ref-type="fig"}](#fig4){ref-type="fig"}B) are needed to produce this effect. This is not only due to the different redox potentials of GSH and NADH but also depends on the inhibition mechanism ([Figure [7](#fig7){ref-type="fig"}](#fig7){ref-type="fig"}), as can be seen in the kinetics (compare [Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}C,D).

In most cases, the addition of AO~red~ to the luminol reaction leads to a delay of light emission ([Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}A--C), and the delay time is dependent on the AO~red~ concentration (Supporting Information, [Figure S2B](http://pubs.acs.org/doi/suppl/10.1021/acsomega.8b01261/suppl_file/ao8b01261_si_001.pdf)). This is in agreement with previous reports^[@ref10],[@ref11],[@ref24]−[@ref28]^ and reveals that AO~red~ is oxidized in the course of the reaction (mechanisms \#1 and \#2; [Figure [7](#fig7){ref-type="fig"}](#fig7){ref-type="fig"}A,B). It implies that light emission resumes when all AO~red~ in the reaction cocktail is consumed ([Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}A--C). However, when AO~red~ inactivates the catalyst (mechanism \#3; [Figure [7](#fig7){ref-type="fig"}](#fig7){ref-type="fig"}C), then the reaction is quenched with no delayed resumption of light. This effect is seen when Cyt *c*-catalyzed luminescence is quenched by NADH ([Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}D).

It is also possible that different quenching mechanisms ([Figure [7](#fig7){ref-type="fig"}](#fig7){ref-type="fig"}) are working simultaneously. This is evident when the luminescence quenching of the Cyt *c*-catalyzed reaction by GSH (pink symbols in [Figure [4](#fig4){ref-type="fig"}](#fig4){ref-type="fig"}A) is compared with the inhibition of the HRP-catalyzed reaction (green symbols in [Figure [4](#fig4){ref-type="fig"}](#fig4){ref-type="fig"}A). The inhibitory effect on Cyt *c* follows a simple sigmoid curve. Here, a single IC~50~ value of 41 μM could be deduced by fitting a four-parameter logistic curve to the data, which reveals an apparent single inhibition mechanism ([Supporting Information](http://pubs.acs.org/doi/suppl/10.1021/acsomega.8b01261/suppl_file/ao8b01261_si_001.pdf), Figure S3.2A). The inhibition of HRP by GSH, in contrast, is of a biphasic sigmoidal shape, revealing two IC~50~ values (4.3 and 276 μM; [Supporting Information](http://pubs.acs.org/doi/suppl/10.1021/acsomega.8b01261/suppl_file/ao8b01261_si_001.pdf), Figure S3.2B) and thus two different inhibition mechanisms occurring at different GSH concentrations. The first (IC~50~ = 4.3 μM) is possibly due to the role of GSH as an electron donor of the peroxidase cycle. The second (IC~50~ = 276 μM) may be caused by the reduction of disulfide bonds in the HRP and thus refolding of the protein. Cyt *c* lacks disulfide bonds, and no biphasic sigmoid is seen ([Supporting Information](http://pubs.acs.org/doi/suppl/10.1021/acsomega.8b01261/suppl_file/ao8b01261_si_001.pdf), Figure S3.2A).

In conclusion, the curves showing the degree of luminescence quenching depending on the concentration of the reducing agent (AO~red~) are characteristic for each catalyst ([Figure [4](#fig4){ref-type="fig"}](#fig4){ref-type="fig"}; [Supporting Information](http://pubs.acs.org/doi/suppl/10.1021/acsomega.8b01261/suppl_file/ao8b01261_si_001.pdf), Figures S3.1; S3.2). In connection with the time kinetics of the inhibited luminescence ([Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}), they are able to unveil the details about both the quenching mechanisms and the relative redox potentials of the components involved (i.e., H~2~O~2~, catalyst, luminol, and AO~red~).

Can the Catalytic Heme Core Be Protected against "Suicide Inactivation"? {#sec3.2}
------------------------------------------------------------------------

The inactivation of peroxidases by excess \[H~2~O~2~\] limits their use in many applications. Consequently, there have been many approaches to prevent "suicide inactivation".^[@ref1]−[@ref9]^ A reasonable concentration of the reducing substrate is sufficient to limit the inactivation ([Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}; [Supporting Information](http://pubs.acs.org/doi/suppl/10.1021/acsomega.8b01261/suppl_file/ao8b01261_si_001.pdf), Table S1.1). The effect of LH^--^ is also seen with Cyt *c* ([Supporting Information](http://pubs.acs.org/doi/suppl/10.1021/acsomega.8b01261/suppl_file/ao8b01261_si_001.pdf), Figure S1). The oxidizing substrate H~2~O~2~ is of less harm as long as there is enough reducing substrate LH^--^ delivering electrons to the catalyst, shielding it from over-oxidation. As mentioned above, the ratio of both substrates (\[LH^--^\]/\[H~2~O~2~\]) gives rise to the shielding effect, and a proper balance can achieve a long-lasting glow.

Some phenolic hydrogen donors (AH) enhance the light emission when added to the luminol reaction. These so-called "enhancers"^[@ref14],[@ref29]^ also shift the "suicide inactivation" of HRP to higher \[H~2~O~2~\] ([Figure [6](#fig6){ref-type="fig"}](#fig6){ref-type="fig"}; [Supporting Information](http://pubs.acs.org/doi/suppl/10.1021/acsomega.8b01261/suppl_file/ao8b01261_si_001.pdf), Table S4.1) as was observed with luminol ([Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}; [Supporting Information](http://pubs.acs.org/doi/suppl/10.1021/acsomega.8b01261/suppl_file/ao8b01261_si_001.pdf), Table S1.1).

Seven reactions are crucial to understand the enhanced peroxidase luminol cycle ([Supporting Information](http://pubs.acs.org/doi/suppl/10.1021/acsomega.8b01261/suppl_file/ao8b01261_si_001.pdf), Table S4.2^[@ref20],[@ref30]^). The enhancer mechanism is similar to the antioxidative mechanism \#2 proposed above ([Figure [7](#fig7){ref-type="fig"}](#fig7){ref-type="fig"}B), but with AH instead of LH^--^ and LH^--^ instead of AO~red~ ([Figure [8](#fig8){ref-type="fig"}](#fig8){ref-type="fig"}B). It implies that (i) AH has a more negative redox potential relative to cytochrome *c* peroxidase compound I (CMPI) and CMPII and (ii) LH^--^ has a more negative redox potential relative to the oxidized product A^•^. This suggests the following ranking of the involved components in terms of their relative redox potentials: A^•^ \> L^--•^ ≫ CMPI ≥ CMPII ≫ LH^--^ \> AH.

![Proposed "ping-pong" mechanisms of the enhanced catalytic peroxidative cycle and the subsequent luminol reaction. (A) "Normal" luminol reaction without an enhancer and (B) luminol reaction enhanced by a redox mediator (AH). This implies that AH works as an intermediate electron donor pool, which is favored by the catalyst as a substrate over LH^--^. The radical A^•^ is able to join in electron exchange with LH^--^ to produce L^--•^ and thus multiplies the oxidation power and turnover of the catalyst. This drastically increases the light yield. Schemes are adapted from ref ([@ref10]). Numbers represent equations eqs S1--S7 in the [Supporting Information](http://pubs.acs.org/doi/suppl/10.1021/acsomega.8b01261/suppl_file/ao8b01261_si_001.pdf) (Table S4.2).](ao-2018-01261f_0008){#fig8}

The effect of enhancers on the light yield can be summarized by three intertwined mechanisms in [Figure [8](#fig8){ref-type="fig"}](#fig8){ref-type="fig"}B:\#1The enzyme (HRP) accepts the enhancer (AH) as an immediate electron donor substrate more effectively than luminol (LH^--^) because AH has a more negative redox potential than LH^--^ and because AH is more similar to the phenolic substrates encountered by the enzyme in vivo than LH^--^.\#2The electron transfer between A^--•^ and LH^--^ is much more efficient than between HRP and LH^--^, yielding much more light when AH is present.\#3AH suppresses the "suicide inactivation" and protects the heme core of HRP from being destroyed by H~2~O~2~ and thereby prevents a decay of light yield.

The enhancing effect of phenolic compounds ([Figure [5](#fig5){ref-type="fig"}](#fig5){ref-type="fig"}; [Supporting Information](http://pubs.acs.org/doi/suppl/10.1021/acsomega.8b01261/suppl_file/ao8b01261_si_001.pdf), Figure S4.1) can only be observed with HRP. The luminol reaction catalyzed by the other heme compounds tested here could not be enhanced in this way. This confirms that HRP is a genuine peroxidase and is thus much more than just a catalytic heme embedded in an inert protein shell. Peroxidases such as HRP evolved in plants specifically to process a broad spectrum of phenolic compounds. "Pseudo"-peroxidases (e.g., Cyt *c* and Hb), in contrast, do not have this substrate spectrum and only resemble the catalytic action of hemin. In terms of peroxidase activity, the polypeptides of "pseudo"-peroxidases simply fulfill an "egg-cup" function to hold the catalytic porphyrin-coordinated iron in place.

The enhancing effect of phenol derivatives on the HRP-catalyzed reaction is prominent as long as \[H~2~O~2~\] \< 10 mM ([Figure [6](#fig6){ref-type="fig"}](#fig6){ref-type="fig"}; [Supporting Information](http://pubs.acs.org/doi/suppl/10.1021/acsomega.8b01261/suppl_file/ao8b01261_si_001.pdf), Figure S4.2). At higher \[H~2~O~2~\], the differences between the luminescence from enhanced and nonenhanced reactions are less because of the "suicide inactivation".

The inactivation of the peroxidase activity is an inherent property of heme. Therefore, any attempts to make peroxidases less sensitive to peroxide inactivation by molecular and genetic engineering must focus on the development of means of arresting over-oxidation. This task, however, presents a dilemma. On the one hand, the heme must be shielded from too much peroxide. On the other hand, shielding must not prevent access of heme to the reducing substrate. Nevertheless, the report of the Cyt *c* triple mutant (N52I; Y67F; C102T) demonstrates that it is possible to solve this problem.^[@ref31]^

Luminol Reaction and Assay Design---Specific Considerations {#sec3.3}
-----------------------------------------------------------

Light from luminol reactions is widely used in many different applications (details in [Supporting Information 5](http://pubs.acs.org/doi/suppl/10.1021/acsomega.8b01261/suppl_file/ao8b01261_si_001.pdf)). Luminescence-based assays are nevertheless sometimes less accepted because of their alleged lack of robustness and reproducibility. This apparent disadvantage is due to the measuring principle with almost black background (i.e., large signal-to-background ratio) and the exceptional sensitivity of modern photodetectors. Even tiny variations in pH, \[LH^--^\], \[H~2~O~2~\], \[HRP\], or temperature will have an impact on the photon flux produced by the reaction. In addition, the presence of enhancers and the diversity of other compounds that are able to catalyze, boost, or otherwise influence the luminol reaction also give rise to problems.

A principal goal, when optimizing luminometric assays, is to obtain a maximum period of long-lived light output ("glow") at a minimum of effort and cost. This means that buffer conditions and concentrations of the catalyst, H~2~O~2~, and luminol must be appropriately balanced. In particular, the assay pH represents a dilemma because genuine peroxidases work best at pH ≤ 9 and the luminol reaction requires alkaline pH ≥ 9. This is detailed in [Supporting Information 6](http://pubs.acs.org/doi/suppl/10.1021/acsomega.8b01261/suppl_file/ao8b01261_si_001.pdf). In addition, many more factors such as detergents,^[@ref32]^ organic solvents such as dimethyl sulfoxide (DMSO),^[@ref33],[@ref34]^ viscosity, ionic strength,^[@ref20]^ halides,^[@ref35]^ and the inadvertent presence of transition metals should also be considered in assay design and improvement of assay performance.

Luminol assays with catalytic mechanisms based on free transition metals are used to quantify these elements^[@ref36]^ or \[H~2~O~2~\].^[@ref37]^ However, for \[H~2~O~2~\] quantification, a peroxidase-based chemistry including enhancers is preferred.^[@ref38]−[@ref40]^

For the quantification of AOs, two strategies are feasible.1On the one hand, the time of luminescence delay ([Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}A--C) is a quantitative measure of antioxidative capacity in the sample ([Supporting Information](http://pubs.acs.org/doi/suppl/10.1021/acsomega.8b01261/suppl_file/ao8b01261_si_001.pdf), Figure S2B). This requires a signal recording period which comprises the whole dark period after sample application until light emission resumes.^[@ref10]^ Consequently, the recording period varies with the amount of AOs in the samples. This way of assaying AOs is not only time-consuming but also inconvenient to implement into automated plate reader assays. It requires appropriate sample dilution prior to assaying to meet the recording time defined with the assay.2On the other hand, the extent of luminescence quenching can be used to quantify AOs. This appears the more reasonable method because it requires only a defined short time period after sample addition and also allows the quantification of reducing agents which quench luminescence via catalyst reduction. In addition, HRP is probably not the optimal catalyst for AO assays when the samples contain enhancers ([Figure [5](#fig5){ref-type="fig"}](#fig5){ref-type="fig"}; [Supporting Information](http://pubs.acs.org/doi/suppl/10.1021/acsomega.8b01261/suppl_file/ao8b01261_si_001.pdf), Figure S4.1) as these compounds antagonize the quenching effect of other reducing analytes and thus lead to erroneous results. Consequently, catalysts insensitive to enhancers, such as Cyt *c*, Hb, or Hemin, are preferable for AO assays.^[@ref25]^

Any luminol-based assay, working under well-defined laboratory conditions, does not necessarily prove valid when "real" samples are analyzed. "Real" samples are often neither processed nor sufficiently pure to meet the required assay conditions, and their complex compound matrix can interfere with the luminol reaction. Consequently, assay results based on the luminol reaction are notorious for misinterpretations when real samples are applied without circumspection. This is particularly problematical, when the luminol reaction is used in forensic chemistry, and the data obtained are used as evidence before a court.^[@ref41]−[@ref45]^ In such cases, several different methods^[@ref46]^ have to be applied to substantiate the result.

In summary, the following results can be listed:\#1The reducing substrate luminol delivers electrons to heme and thus prevents its disintegration by H~2~O~2~ ([Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}; [Supporting Information](http://pubs.acs.org/doi/suppl/10.1021/acsomega.8b01261/suppl_file/ao8b01261_si_001.pdf), Figure S1 and Table S1.1). This protective antioxidative effect is efficient as long as there is a balance between \[H~2~O~2~\], \[LH^--^\], and \[catalyst\] in the assay. "Suicide inactivation" occurs when \[H~2~O~2~\] exceeds \[LH^--^\] by orders of magnitude.\#2Nonsubstrate AOs or reducing agents lead to a reduction and/or a delay of luminescence ([Figures [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"} and [4](#fig4){ref-type="fig"}; [Supporting Information](http://pubs.acs.org/doi/suppl/10.1021/acsomega.8b01261/suppl_file/ao8b01261_si_001.pdf), Figures S2--S3.1).\#3The HRP-catalyzed luminol reaction can be enhanced by diverse aromatic hydrogen donors ([Figure [5](#fig5){ref-type="fig"}](#fig5){ref-type="fig"}; [Supporting Information](http://pubs.acs.org/doi/suppl/10.1021/acsomega.8b01261/suppl_file/ao8b01261_si_001.pdf) Figure S4.1). Such enhancers exhibit, like luminol, a protective antioxidative effect and prevent "suicide inactivation" ([Figure [6](#fig6){ref-type="fig"}](#fig6){ref-type="fig"}; [Supporting Information](http://pubs.acs.org/doi/suppl/10.1021/acsomega.8b01261/suppl_file/ao8b01261_si_001.pdf), Figure S4.2; Table S4.1).\#4Only the luminol reaction catalyzed by the genuine peroxidase (HRP) can be enhanced. Other heme catalysts do not give rise to the enhancement of the light yield in the presence of aromatic hydrogen donors ([Figure [5](#fig5){ref-type="fig"}](#fig5){ref-type="fig"}; [Supporting Information](http://pubs.acs.org/doi/suppl/10.1021/acsomega.8b01261/suppl_file/ao8b01261_si_001.pdf), Figure S4.1).

Conclusions {#sec4}
===========

Because the luminol reaction is complex (details in [Supporting Information S6](http://pubs.acs.org/doi/suppl/10.1021/acsomega.8b01261/suppl_file/ao8b01261_si_001.pdf)) and influenced by many diverse parameters, the interpretation of luminol luminescence is difficult when the assay data are obtained from the samples containing a complex compound matrix. Thus, the design of luminometric assays requires precise knowledge about the chemistry, as well as considerations about the compound matrix in the samples to be assayed. The results presented here add to our knowledge on the intertwined interactions of substrates, redox modulators, and catalysts of the luminol reaction and thereby draw attention to factors that should be considered for optimal assay design.

Experimental Section {#sec5}
====================

Chemicals {#sec5.1}
---------

Ascorbate (Sigma, \#A7506), benzidine (Sigma \#31614), calcium chloride (CaCl~2~·6H~2~O; Roth \#T886), coumaric acid (Sigma \#C9008), Cu/Zn-superoxide dismutase from bovine liver (Sigma \#S8409), cytochrome *c* from equine heart (Sigma \#C2506 and BioChemica/Fluka \#30400), DMSO (Roth \#4720), dithiothreitol (Roth\#6908), ethylenediaminetetraacetic acid (Aldrich \#E2,628-2), FeEDDHA (Duchefa \#F0527), ferrous sulfate (Fe^II^SO~4~·7H~2~O; Roth \#P015 and Merck \#3965), ferric nitrate (Fe^III^NO~3~·9H~2~O; Fluka \#44949), GSH (Roth \#6382), heminchlorid (Roth \#7629), hemoglobin from bovine blood (Sigma \#H2500), hydrochloric acid (HCl 34%; Roth \#4625), hydrogen peroxide (H~2~O~2~ 30%; Roth \#8070 and Merck \#1.08597), IP (Fluka \#58020), luminol (Roth \#4203), mannitol (Roth \#4175), NADH (Roth \#AE12), HRP (Sigma \#P6140), potassium hydroxide (KOH; Roth \#5658), sodium sulfite (Na~2~SO~3~; Fluka \#71988), TRIS ultrapure (ICN Biomedicals \#77861), trolox (KJ Ross-Petersen Aps; Denmark and Aldrich \#23881), and uric acid (UA, Sigma \#U2625).

Stock Solutions and Buffers {#sec5.2}
---------------------------

10× TRIS Stock: Tris/HCl 1 M; adjusted at 28 ± 2 °C to a desired pH; Tris working buffer: Tris/HCl 100 mM diluted 1:10 from TRIS Stock; KOH 5 M Stock in H~2~O; luminol stock 2 M in 5 M KOH; TriLu buffer: luminol in a working buffer diluted from luminol stock to the desired concentration; and a starter solution for the luminol reaction: H~2~O~2~ in Tris working buffer.

Specific Material and Instrumentation {#sec5.3}
-------------------------------------

Luminescence was recorded using 96-well microtiter plates (MTPs) with white flat bottom (Greiner Bio-One \#655075) readout by a plate reader Infinite M200 pro with injection unit (Tecan, Crailsheim, Germany).

Methods {#sec5.4}
-------

Luminescence recording was performed at 28 °C with the plate reader specified above. Prefilled MTPs were incubated for 1 h at 28 °C with sporadic shaking prior to recording. Reactions were started by dispensing the complementary assay compounds to prefilled wells.

To study the luminol-derived light yield and its dependence on the hydrogen peroxide concentration and pH, four H~2~O~2~ dilution series (1:2) were established on an MTP. The dilution series were set up on two rows (150 μL each well). After incubation (1 h at 28 °C), the reactions were started by dispensing 50 μL of the catalyst dissolved in TriLu buffer.

To unravel the effects of the reducing compounds, the MTPs were prefilled with the dilution series of the respective compound in TriLu buffer supplemented with the correct catalyst concentration (150 μL each well), and reactions were started by injecting 50 μL of H~2~O~2~ as the starter solution.

Detailed assay conditions for each experiment are given in the figure legends.

The Supporting Information is available free of charge on the [ACS Publications website](http://pubs.acs.org) at DOI: [10.1021/acsomega.8b01261](http://pubs.acs.org/doi/abs/10.1021/acsomega.8b01261).Half-inhibitory peroxide concentrations IC~50~ of the HRP-catalyzed luminol reaction and its dependence on the luminol concentration \[LH^--^\]; dependence of luminescence on \[H~2~O~2~\] and the luminol concentration \[LH^--^\] with Cyt~*c*~ as the catalyst; half-inhibitory peroxide concentrations IC~50~ of the HRP-catalyzed luminol reaction and its dependence on the GSH concentration; effect of GSH on the kinetics of the luminol reaction catalyzed by HRP; comparison of the initial quenching effects of reducing agents on the luminol reaction catalyzed by diverse catalysts; quenching effect of GSH on the luminol reaction catalyzed by Cyt~*c*~ and HRP; dependence of half-inhibitory H~2~O~2~ concentrations IC~50~ on the IP concentration \[IP\]; effect of benzidine and coumarin on the luminol reaction catalyzed by diverse catalysts; dependence of luminescence on \[H~2~O~2~\] in the presence of benzidine; reaction equations representing the mechanism of the enhanced catalytic peroxidative cycle and the luminol reaction catalyzed by it; luminol-based quantitative assays; summary of the luminol reaction; structures of luminol, intermediates, and the product of the reaction; light generation by the luminol reaction: the general principle; and catalytic peroxidative cycle and the luminol reaction catalyzed by it ([PDF](http://pubs.acs.org/doi/suppl/10.1021/acsomega.8b01261/suppl_file/ao8b01261_si_001.pdf))
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AO

:   antioxidant

AP

:   aminophthalate

AQ

:   azaquinone

CMP

:   compound

cps

:   counts per second

Cyt *c*

:   cytochrome *c*

*E*~LY~

:   light yield efficiency

FHW

:   Fenton--Haber--Weiss

Hb

:   hemoglobin

HRP

:   horseradish peroxidase

*I*~LY~

:   integrated light yield

LH^--^

:   luminol monoanion

MTP

:   microtiter plate

ROS

:   reactive oxygen species

SOD

:   superoxide dismutase

any molecular species "M" in square brackets (e.g., \[M\])

:   denotes the concentration of this substance
